INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) has entered into a settlement agreement with
generic companies to resolve pending patent litigation in the U.S.
District Court for the Eastern District of Virginia regarding the Cialis®
(tadalafil) unit dose patent. This patent was previously set to
expire on April 26, 2020. As part of
the agreement, Cialis exclusivity is now expected to end at the
earliest on September 27, 2018.
"The unit dose patent for Cialis is valid and infringed by
companies seeking to market a generic version of Cialis. This is a
royalty-bearing license agreement that provides us with more
certainty regarding our U.S. exclusivity," said Michael J. Harrington, senior vice president and
general counsel for Lilly. "Protection of intellectual property and
the assurance of market exclusivity are extremely important to
Lilly as we work to support the development of the next generation
of innovative medicines."
Patent expiration for Adcirca (tadalafil) is still expected on
November 21, 2017, or on May 21, 2018, if the U.S. Food and Drug
Administration grants the company's application for pediatric
exclusivity.
There will be no change to the company's 2017 financial guidance
or mid-term expectations through the remainder of the decade as a
result of this settlement.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
http://newsroom.lilly.com/social-channels. C-LLY
This release contains forward-looking statements regarding
Cialis patent litigation and related settlement. There can be
no guarantees as to the outcome and results of the settlement.
These statements are based on management's current expectations,
but actual results may differ materially. Other risk factors that
may affect the company's results can be found in the company's
latest Forms 10-K and 10-Q filed with the U.S. Securities and
Exchange Commission.
Refer
to:
|
Lauren Zierke;
lauren_zierke@lilly.com; 317-277-6524 (Media)
|
|
Phil Johnson;
johnson_philip_l@lilly.com; 317-655-6874 (Investors)
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/lilly-reaches-settlement-agreement-in-us-cialis-patent-litigation-300486978.html
SOURCE Eli Lilly and Company